Teclistamab-Associated Sclerouveitis with Hypopyon

Abstract

Purpose: To report a case of presumed teclistamab-associated sclerouveitis with hypopyon. Methods: Case report. Results: A 62-year-old female with relapsed refractory multiple myeloma presented with right eye pain and decreased vision one week after starting teclistamab, and was found to have sclerouveitis with hypopyon. She received intravitreal vancomycin and ceftazidime due to concern for infectious endophthalmitis, but cultures were negative. Systemic workup for infectious and inflammatory etiologies was unremarkable. Her signs and symptoms improved with topical steroids and a one-week pause in teclistamab. This case constituted a Naranjo Adverse Drug Reaction Probability Scale score of 5, representing a “probable” association. Conclusion: Teclistamab, a novel bispecific antibody recently approved for the treatment of relapsed or refractory multiple myeloma, may be associated with sclerouveitis with hypopyon.

Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient

“…Additionally, hypogammaglobulinemia, induced by MM's impact on antibody production and further compounded by treatment with bispecific antibodies like teclistamab, which can deplete plasma cells, necessitates vigilant monitoring and preventive measures [12]. Unique cases such as teclistamab-associated sclerouveitis or teclistamab-associated neurotoxicities have also been recently reported [13,14].…”